[go: up one dir, main page]

MA47106A - Formulations d'anticorps anti-tnf alpha - Google Patents

Formulations d'anticorps anti-tnf alpha

Info

Publication number
MA47106A
MA47106A MA047106A MA47106A MA47106A MA 47106 A MA47106 A MA 47106A MA 047106 A MA047106 A MA 047106A MA 47106 A MA47106 A MA 47106A MA 47106 A MA47106 A MA 47106A
Authority
MA
Morocco
Prior art keywords
tnf alpha
antibody formulations
alpha antibody
formulations
tnf
Prior art date
Application number
MA047106A
Other languages
English (en)
Inventor
Joy Brennan
William J Callahan
Rahul Rajan Kaushik
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA47106A publication Critical patent/MA47106A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047106A 2016-12-21 2017-12-20 Formulations d'anticorps anti-tnf alpha MA47106A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662437640P 2016-12-21 2016-12-21

Publications (1)

Publication Number Publication Date
MA47106A true MA47106A (fr) 2019-10-30

Family

ID=61006357

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047106A MA47106A (fr) 2016-12-21 2017-12-20 Formulations d'anticorps anti-tnf alpha

Country Status (4)

Country Link
US (2) US20200087390A1 (fr)
EP (3) EP4467565A2 (fr)
MA (1) MA47106A (fr)
WO (1) WO2018119142A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020216847A1 (fr) * 2019-04-23 2020-10-29 Sanofi Formulations d'anticorps stables et à faible viscosité et leurs utilisations
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
EP4384217A1 (fr) * 2021-08-12 2024-06-19 Amgen Inc. Formulations d'anticorps

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MX2015003007A (es) * 2012-09-07 2015-06-05 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab.
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
SI2946765T1 (sl) * 2014-05-23 2016-11-30 Ares Trading S.A. Tekoči farmacevtski sestavek
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016103093A1 (fr) * 2014-12-23 2016-06-30 Pfizer Inc. Formulation d'anticorps aqueuse stable pour des anticorps anti tnf alpha
US20180016333A1 (en) * 2015-01-28 2018-01-18 Mabxience, S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
RU2017131618A (ru) * 2015-02-13 2019-03-13 Санофи Стабильный жидкий состав для моноклональных антител
WO2016162819A1 (fr) * 2015-04-07 2016-10-13 Lupin Limited Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha

Also Published As

Publication number Publication date
EP3824906A1 (fr) 2021-05-26
WO2018119142A1 (fr) 2018-06-28
EP3558363A1 (fr) 2019-10-30
US20230151086A1 (en) 2023-05-18
EP4467565A2 (fr) 2024-11-27
US20200087390A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
MA49043A (fr) Formulation stable d'anticorps
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA46525A (fr) Anticorps anti-lag-3 et compositions
EP3359573A4 (fr) Marquage d'anticorps
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA47268A (fr) Anticorps anti-gpc3
MA49726A (fr) Formulation d'anticorps anti-cgrp
EP3430731A4 (fr) Architecture d'iugw
EP3423089A4 (fr) Anticorps anti-tigit
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA44236A (fr) Anticorps anti-tgfbêta 2
DK3504241T3 (da) Anti-cd3-antistofformuleringer
MA52366A (fr) Anticorps anti-tl1a optimisés
MA49749A (fr) Anticorps anti-cd137
MA51903A (fr) Formulations d'anticorps b7-h4
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
MA44054A (fr) Plateforme d'anticorps bispécifique
MA52152A (fr) Anticorps
EP3618865A4 (fr) Anticorps humain anti-sémaphorine 4d
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha